Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.

Sze JH, Raninga PV, Nakamura K, Casey M, Khanna KK, Berners-Price SJ, Di Trapani G, Tonissen KF.

Redox Biol. 2019 Aug 28;28:101310. doi: 10.1016/j.redox.2019.101310. [Epub ahead of print]

2.

Simultaneous Targeting of DNA Replication and Homologous Recombination in Glioblastoma with a Polyether Ionophore.

Lim YC, Ensbey KS, Offenhäuser C, D'Souza RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli V, Mahboubi B, Smith F, Jeffree RL, Wiesmüeller L, Wiegmans AP, Bain A, Lombard FJ, Roberts TL, Khanna KK, Lavin MF, Baek K, Hamerlik P, Johns TG, Coster MJ, Boyd AW, Day BW.

Neuro Oncol. 2019 Aug 30. pii: noz159. doi: 10.1093/neuonc/noz159. [Epub ahead of print]

PMID:
31504812
3.

First meiotic anaphase requires Cep55-dependent inhibitory cyclin-dependent kinase 1 phosphorylation.

Zhou C, Hancock JL, Khanna KK, Homer HA.

J Cell Sci. 2019 Sep 26;132(18). pii: jcs233379. doi: 10.1242/jcs.233379.

PMID:
31427428
4.

GSK3-β Stimulates Claspin Degradation via β-TrCP Ubiquitin Ligase and Alters Cancer Cell Survival.

Cabrera E, Raninga P, Khanna KK, Freire R.

Cancers (Basel). 2019 Jul 29;11(8). pii: E1073. doi: 10.3390/cancers11081073.

5.

A Comprehensive Review on Current Advances in Peptide Drug Development and Design.

Lee AC, Harris JL, Khanna KK, Hong JH.

Int J Mol Sci. 2019 May 14;20(10). pii: E2383. doi: 10.3390/ijms20102383. Review.

6.

Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.

Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid LE, McCart Reed AE, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris JM, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.

Ann Oncol. 2019 Jul 1;30(7):1071-1079. doi: 10.1093/annonc/mdz132.

7.

Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.

Raninga PV, Lee AC, Sinha D, Shih YY, Mittal D, Makhale A, Bain AL, Nanayakarra D, Tonissen KF, Kalimutho M, Khanna KK.

Int J Cancer. 2019 May 15. doi: 10.1002/ijc.32410. [Epub ahead of print]

PMID:
31090219
8.

Mechanisms of Genomic Instability in Breast Cancer.

Duijf PHG, Nanayakkara D, Nones K, Srihari S, Kalimutho M, Khanna KK.

Trends Mol Med. 2019 Jul;25(7):595-611. doi: 10.1016/j.molmed.2019.04.004. Epub 2019 May 8. Review.

PMID:
31078431
9.

Correction: DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.

Hernández-Pérez S, Cabrera E, Salido E, Lim M, Reid L, Lakhani SR, Khanna KK, Saunus JM, Freire R.

Oncogene. 2019 Jun;38(24):4886. doi: 10.1038/s41388-019-0753-2.

PMID:
31068665
10.

MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells.

Yang RM, Nanayakkara D, Kalimutho M, Mitra P, Khanna KK, Dray E, Gonda TJ.

Oncogene. 2019 Jun;38(26):5239-5249. doi: 10.1038/s41388-019-0789-3. Epub 2019 Apr 10.

PMID:
30971760
11.

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer.

Kalimutho M, Sinha D, Mittal D, Srihari S, Nanayakkara D, Shafique S, Raninga P, Nag P, Parsons K, Khanna KK.

J Exp Clin Cancer Res. 2019 Feb 18;38(1):85. doi: 10.1186/s13046-019-1075-5.

12.

RAD51 paralogs promote genomic integrity and chemoresistance in cancer by facilitating homologous recombination.

Harris JL, Rabellino A, Khanna KK.

Ann Transl Med. 2018 Dec;6(Suppl 2):S122. doi: 10.21037/atm.2018.12.30. No abstract available.

13.

Patterns of Genomic Instability in Breast Cancer.

Kalimutho M, Nones K, Srihari S, Duijf PHG, Waddell N, Khanna KK.

Trends Pharmacol Sci. 2019 Mar;40(3):198-211. doi: 10.1016/j.tips.2019.01.005. Epub 2019 Feb 6. Review.

PMID:
30736983
14.

Mitotic slippage: an old tale with a new twist.

Sinha D, Duijf PHG, Khanna KK.

Cell Cycle. 2019 Jan;18(1):7-15. doi: 10.1080/15384101.2018.1559557. Epub 2019 Jan 2.

PMID:
30601084
15.

RNA interference to enhance radiation therapy: Targeting the DNA damage response.

Ratnayake G, Bain AL, Fletcher N, Howard CB, Khanna KK, Thurecht KJ.

Cancer Lett. 2018 Dec 28;439:14-23. doi: 10.1016/j.canlet.2018.09.011. Epub 2018 Sep 18. Review.

PMID:
30240587
16.

Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.

Prasanna T, Wu F, Khanna KK, Yip D, Malik L, Dahlstrom JE, Rao S.

Cancer Sci. 2018 Nov;109(11):3383-3392. doi: 10.1111/cas.13799. Epub 2018 Oct 20. Review.

17.

Serendipity, luck and hard work.

Khanna KK.

Nat Cell Biol. 2018 Sep;20(9):1004. doi: 10.1038/s41556-018-0170-8. No abstract available.

PMID:
30154556
18.

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.

Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, Duijf PH, Vennin C, Raninga P, Nanayakkara D, Mittal D, Saunus JM, Lakhani SR, López JA, Spring KJ, Timpson P, Gabrielli B, Waddell N, Khanna KK.

EMBO Mol Med. 2018 Sep;10(9). pii: e8566. doi: 10.15252/emmm.201708566.

19.

Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling.

Sinha D, Kalimutho M, Bowles J, Chan AL, Merriner DJ, Bain AL, Simmons JL, Freire R, Lopez JA, Hobbs RM, O'Bryan MK, Khanna KK.

FASEB J. 2018 Sep;32(9):4984-4999. doi: 10.1096/fj.201701096RR. Epub 2018 Apr 17.

PMID:
29683733
20.

The breast cancer antigen 5T4 interacts with Rab11, and is a target and regulator of Rab11 mediated trafficking.

Harris JL, Dave K, Gorman J, Khanna KK.

Int J Biochem Cell Biol. 2018 Jun;99:28-37. doi: 10.1016/j.biocel.2018.03.002. Epub 2018 Mar 13.

PMID:
29549047
21.

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.

Johnson J, Bessette DC, Saunus JM, Smart CE, Song S, Johnston RL, Cocciardi S, Rozali EN, Johnstone CN, Vargas AC, Kazakoff SH, BioBank VC, Khanna KK, Lakhani SR, Chenevix-Trench G, Simpson PT, Nones K, Waddell N, Al-Ejeh F.

Breast Cancer Res Treat. 2018 Jul;170(1):179-188. doi: 10.1007/s10549-018-4719-9. Epub 2018 Feb 21.

PMID:
29468485
22.

LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.

Boulding T, McCuaig RD, Tan A, Hardy K, Wu F, Dunn J, Kalimutho M, Sutton CR, Forwood JK, Bert AG, Goodall GJ, Malik L, Yip D, Dahlstrom JE, Zafar A, Khanna KK, Rao S.

Sci Rep. 2018 Jan 8;8(1):73. doi: 10.1038/s41598-017-17913-x.

23.

Differentiation of Human Induced Pluripotent or Embryonic Stem Cells Decreases the DNA Damage Repair by Homologous Recombination.

Mujoo K, Pandita RK, Tiwari A, Charaka V, Chakraborty S, Singh DK, Hambarde S, Hittelman WN, Horikoshi N, Hunt CR, Khanna KK, Kots AY, Butler EB, Murad F, Pandita TK.

Stem Cell Reports. 2017 Nov 14;9(5):1660-1674. doi: 10.1016/j.stemcr.2017.10.002. Epub 2017 Nov 2.

24.

Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours.

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MCJ, Bruxner TJC, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Hiriyur Nagaraj S, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Vittoria Davì M, Landoni L, Malpaga A, Miotto M, Whitehall VLJ, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LMS, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative, Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2017 Oct 26;550(7677):548. doi: 10.1038/nature24026. Epub 2017 Sep 27.

PMID:
28953865
25.

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Saunus JM, Smart CE, Kutasovic JR, Johnston RL, Kalita-de Croft P, Miranda M, Rozali EN, Vargas AC, Reid LE, Lorsy E, Cocciardi S, Seidens T, McCart Reed AE, Dalley AJ, Wockner LF, Johnson J, Sarkar D, Askarian-Amiri ME, Simpson PT, Khanna KK, Chenevix-Trench G, Al-Ejeh F, Lakhani SR.

Breast Cancer Res Treat. 2018 Jan;167(1):289-301. doi: 10.1007/s10549-017-4496-x. Epub 2017 Sep 9.

PMID:
28889351
26.

Signaling to the Epigenome: New Insights into the Roles of Nuclear Signaling Kinases in the Context of the Immune System and Cancer.

Lim PS, Khanna KK, Rao S.

Front Immunol. 2017 Aug 21;8:980. doi: 10.3389/fimmu.2017.00980. eCollection 2017. No abstract available.

27.

Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families.

Li J, Li H, Makunin I; kConFab Investigators, Thompson BA, Tao K, Young EL, Lopez J, Camp NJ, Tavtigian SV, John EM, Andrulis IL, Khanna KK, Goldgar D, Chenevix-Trench G.

Breast Cancer Res Treat. 2017 Dec;166(3):937-949. doi: 10.1007/s10549-017-4469-0. Epub 2017 Aug 24.

28.

Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage.

Betts JA, Moradi Marjaneh M, Al-Ejeh F, Lim YC, Shi W, Sivakumaran H, Tropée R, Patch AM, Clark MB, Bartonicek N, Wiegmans AP, Hillman KM, Kaufmann S, Bain AL, Gloss BS, Crawford J, Kazakoff S, Wani S, Wen SW, Day B, Möller A, Cloonan N, Pearson J, Brown MA, Mercer TR, Waddell N, Khanna KK, Dray E, Dinger ME, Edwards SL, French JD.

Am J Hum Genet. 2017 Aug 3;101(2):255-266. doi: 10.1016/j.ajhg.2017.07.007.

29.

Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells.

Peters AA, Jamaludin SYN, Yapa KTDS, Chalmers S, Wiegmans AP, Lim HF, Milevskiy MJG, Azimi I, Davis FM, Northwood KS, Pera E, Marcial DL, Dray E, Waterhouse NJ, Cabot PJ, Gonda TJ, Kenny PA, Brown MA, Khanna KK, Roberts-Thomson SJ, Monteith GR.

Oncogene. 2017 Nov 16;36(46):6490-6500. doi: 10.1038/onc.2017.234. Epub 2017 Jul 31.

PMID:
28759041
30.

DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.

Hernández-Pérez S, Cabrera E, Salido E, Lim M, Reid L, Lakhani SR, Khanna KK, Saunus JM, Freire R.

Oncogene. 2017 Aug 17;36(33):4817. doi: 10.1038/onc.2017.220. Epub 2017 Jun 26.

PMID:
28650472
31.

Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.

Ward A, Dong L, Harris JM, Khanna KK, Al-Ejeh F, Fairlie DP, Wiegmans AP, Liu L.

Bioorg Med Chem Lett. 2017 Jul 15;27(14):3096-3100. doi: 10.1016/j.bmcl.2017.05.039. Epub 2017 May 15.

PMID:
28545975
32.

DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair.

Tomimatsu N, Mukherjee B, Harris JL, Boffo FL, Hardebeck MC, Potts PR, Khanna KK, Burma S.

J Biol Chem. 2017 Jun 30;292(26):10779-10790. doi: 10.1074/jbc.M116.772475. Epub 2017 May 17.

33.

Identification of ATM-Interacting Proteins by Co-immunoprecipitation and Glutathione-S-Transferase (GST) Pull-Down Assays.

Bain AL, Harris JL, Khanna KK.

Methods Mol Biol. 2017;1599:163-181. doi: 10.1007/978-1-4939-6955-5_13.

PMID:
28477119
34.

DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.

Hernández-Pérez S, Cabrera E, Salido E, Lim M, Reid L, Lakhani SR, Khanna KK, Saunus JM, Freire R.

Oncogene. 2017 Aug 17;36(33):4802-4809. doi: 10.1038/onc.2017.21. Epub 2017 Mar 13. Erratum in: Oncogene. 2017 Jun 26;:. Oncogene. 2019 Jun;38(24):4886.

PMID:
28288134
35.

Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress.

Shi W, Vu T, Boucher D, Biernacka A, Nde J, Pandita RK, Straube J, Boyle GM, Al-Ejeh F, Nag P, Jeffery J, Harris JL, Bain AL, Grzelak M, Skrzypczak M, Mitra A, Dojer N, Crosetto N, Cloonan N, Becherel OJ, Finnie J, Skaar JR, Walkley CR, Pandita TK, Rowicka M, Ginalski K, Lane SW, Khanna KK.

Blood. 2017 May 4;129(18):2479-2492. doi: 10.1182/blood-2016-06-725093. Epub 2017 Mar 7.

36.

Whole-genome landscape of pancreatic neuroendocrine tumours.

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davì MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LM, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative, Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2017 Mar 2;543(7643):65-71. doi: 10.1038/nature21063. Epub 2017 Feb 15. Erratum in: Nature. 2017 Sep 27;:.

PMID:
28199314
37.

Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.

Kalimutho M, Bain AL, Mukherjee B, Nag P, Nanayakkara DM, Harten SK, Harris JL, Subramanian GN, Sinha D, Shirasawa S, Srihari S, Burma S, Khanna KK.

Mol Oncol. 2017 May;11(5):470-490. doi: 10.1002/1878-0261.12040. Epub 2017 Mar 27.

38.

The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells.

Anderson AM, Kalimutho M, Harten S, Nanayakkara DM, Khanna KK, Ragan MA.

Sci Rep. 2017 Jan 4;7:39873. doi: 10.1038/srep39873.

39.

Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer.

Liu C, Rohart F, Simpson PT, Khanna KK, Ragan MA, Lê Cao KA.

Sci Rep. 2016 Sep 26;6:34000. doi: 10.1038/srep34000.

40.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB; GEMO Study Collaborators, Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S; EMBRACE, Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A, Ghoussaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN; KConFab Investigators; Australian Ovarian Cancer Study Group, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemeney LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Massuger LF, Matsuo K, Mazoyer S, McGuffog L, McLean C, McNeish I, Meindl A, Menon U, Mensenkamp AR, Milne RL, Montagna M, Moysich KB, Muir K, Mulligan AM, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Nord S, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olswold C, O'Malley D, Orlow I, Orr N, Osorio A, Park SK, Pearce CL, Pejovic T, Peterlongo P, Pfeiler G, Phelan CM, Poole EM, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Rhenius V, Rhiem K, Risch HA, Rodriguez G, Rossing MA, Rudolph A, Salvesen HB, Sangrajrang S, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Sellers TA, Seynaeve C, Shah M, Shen CY, Shu XO, Sieh W, Singer CF, Sinilnikova OM, Slager S, Song H, Soucy P, Southey MC, Stenmark-Askmalm M, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tchatchou S, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, Toland AE, Tomlinson I, Torres D, Truong T, Tseng CC, Tung N, Tworoger SS, Vachon C, van den Ouweland AM, van Doorn HC, van Rensburg EJ, Van't Veer LJ, Vanderstichele A, Vergote I, Vijai J, Wang Q, Wang-Gohrke S, Weitzel JN, Wentzensen N, Whittemore AS, Wildiers H, Winqvist R, Wu AH, Yannoukakos D, Yoon SY, Yu JC, Zheng W, Zheng Y, Khanna KK, Simard J, Monteiro AN, French JD, Couch FJ, Freedman ML, Easton DF, Dunning AM, Pharoah PD, Edwards SL, Chenevix-Trench G, Antoniou AC, Gayther SA.

Nat Commun. 2016 Sep 7;7:12675. doi: 10.1038/ncomms12675.

41.

FBXO31 protects against genomic instability by capping FOXM1 levels at the G2/M transition.

Jeffery JM, Kalimutho M, Johansson P, Cardenas DG, Kumar R, Khanna KK.

Oncogene. 2017 Feb 16;36(7):1012-1022. doi: 10.1038/onc.2016.268. Epub 2016 Aug 29.

PMID:
27568981
42.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

43.

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis.

Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, Caramia F, Haibe-Kains B, Stagg J, Khanna KK, Loi S, Smyth MJ.

Cancer Res. 2016 Aug 1;76(15):4372-82. doi: 10.1158/0008-5472.CAN-16-0544. Epub 2016 May 24.

44.

High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations.

Johnston RL, Wockner L, McCart Reed AE, Wiegmans A, Chenevix-Trench G, Khanna KK, Lakhani SR, Smart CE.

Breast Cancer Res. 2016 Feb 9;18(1):18. doi: 10.1186/s13058-016-0681-9.

45.

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.

French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, Korbie DJ; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching PA, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Pisterer J, Hillemanns P, Nakanishi T, Yatabe Y, Goodman MT, Lurie G, Matsuno RK, Thompson PJ, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan JM, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut JM, Iversen E, Weber RP, Brennan D, Berchuck A, Pharoah P, Harnett P, Norris MD, Haber M, Goode EL, Lee JS, Khanna KK, Meyer KB, Chenevix-Trench G, deFazio A, Edwards SL, MacGregor S; Ovarian Cancer Association Consortium.

Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047.

46.

Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach.

Srihari S, Kalimutho M, Lal S, Singla J, Patel D, Simpson PT, Khanna KK, Ragan MA.

Mol Biosyst. 2016 Mar;12(3):963-72. doi: 10.1039/c5mb00655d.

PMID:
26805938
47.

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.

Kalimutho M, Parsons K, Mittal D, López JA, Srihari S, Khanna KK.

Trends Pharmacol Sci. 2015 Dec;36(12):822-846. doi: 10.1016/j.tips.2015.08.009. Epub 2015 Nov 1. Review.

PMID:
26538316
48.

Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer.

Liu C, Srihari S, Lal S, Gautier B, Simpson PT, Khanna KK, Ragan MA, Lê Cao KA.

Mol Oncol. 2016 Jan;10(1):179-93. doi: 10.1016/j.molonc.2015.09.007. Epub 2015 Sep 26.

49.

Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.

Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.

Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.

50.

ATM-dependent phosphorylation of MRE11 controls extent of resection during homology directed repair by signalling through Exonuclease 1.

Kijas AW, Lim YC, Bolderson E, Cerosaletti K, Gatei M, Jakob B, Tobias F, Taucher-Scholz G, Gueven N, Oakley G, Concannon P, Wolvetang E, Khanna KK, Wiesmüller L, Lavin MF.

Nucleic Acids Res. 2015 Sep 30;43(17):8352-67. doi: 10.1093/nar/gkv754. Epub 2015 Aug 3.

Supplemental Content

Loading ...
Support Center